PHARMO Institute for Drug Outcomes Research, Van Deventerlaan 30-40, Utrecht, 3528 AE, The Netherlands.
Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands.
ESC Heart Fail. 2022 Aug;9(4):2139-2146. doi: 10.1002/ehf2.13923. Epub 2022 Apr 22.
This population-based case-control study aims to investigate the occurrence of heart failure (HF) among colon and rectal cancer survivors compared with a cancer-free control population taking into account pre-existing cardiovascular risk factors and the influence of treatment.
Colon and rectal cancer survivors diagnosed between 2007 and 2014 were selected from a linked cohort of cancer and primary care data in the Netherlands and matched based on gender, birth year, general practitioner (GP) practice, and follow-up period to cancer-free controls. The occurrence of HF was identified based on GP recorded diagnoses after index date (diagnosis date for cases). A Cox proportional hazards model was used to estimate hazard ratios (HRs), adjusted for age, sex, hypertension, diabetes, and hypercholesterolaemia. A total of 5333 colon cancer cases and 2468 rectal cancer cases could be matched to a total of 31 204 cancer-free controls. A statistically significant increased risk of HF was seen among all cases compared with cancer-free controls (HR 1.33; 95% confidence interval: 1.12-1.59). This was also seen when analysing colon cancer and rectal cancer separately. Being diagnosed with stage IV cancer, having hypertension, or having hypercholesterolaemia statistically significantly increased the risk of HF among colon cancer. Hypertension was a statistically significant risk factor for developing HF among rectal cancer cases.
Colon and rectal cancer survivors are at increased risk for developing HF. More awareness should be created by treating physicians and GPs for this potential increased risk in order to further improve survival.
本基于人群的病例对照研究旨在调查结肠癌和直肠癌幸存者发生心力衰竭(HF)的情况,并与无癌症对照人群进行比较,同时考虑到预先存在的心血管危险因素和治疗的影响。
从荷兰癌症和初级保健数据的关联队列中选择了 2007 年至 2014 年间诊断为结肠癌和直肠癌的幸存者,并根据性别、出生年份、全科医生(GP)实践和随访期与无癌症对照人群进行匹配。HF 的发生是基于 GP 在索引日期(病例的诊断日期)后记录的诊断确定的。使用 Cox 比例风险模型来估计风险比(HR),调整了年龄、性别、高血压、糖尿病和高胆固醇血症。共匹配了 5333 例结肠癌病例和 2468 例直肠癌病例,共 31204 例无癌症对照。与无癌症对照相比,所有病例的 HF 风险均显著增加(HR 1.33;95%置信区间:1.12-1.59)。当分别分析结肠癌和直肠癌时,也观察到了这种情况。被诊断为 IV 期癌症、患有高血压或高胆固醇血症会显著增加结肠癌发生 HF 的风险。高血压是直肠癌患者发生 HF 的一个显著危险因素。
结肠癌和直肠癌幸存者发生 HF 的风险增加。为了进一步提高生存率,治疗医生和全科医生应该对这种潜在的风险增加有更多的认识。